Previous studies investigated the association of TREML2 rs3747742 with cerebrospinal fluid (CSF) biomarkers of AD and found that carriers of C allele had a decreased level of both hyperphosphorylated and total CSF tau (Benitez et al., 2013; Song et al., 2019), indicating that TREML2 rs3747742‐C may decrease AD risk by attenuating neurodegeneration process. This evidence concerns the gene MAPT and Alzheimer disease.